Tempest Therapeutics, Inc. TPST
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-52.88
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$26.3M | — | -$26.8M | $6.7M |
| 2024 | — | -$41.8M | — | -$33.5M | $19.1M |
| 2023 | — | -$29.5M | — | -$27.5M | $26.8M |
| 2022 | — | -$35.7M | — | -$31.6M | $18.1M |
| 2021 | — | -$28.3M | — | -$26.1M | $36.1M |
| 2020 | — | -$19.2M | — | -$19.1M | -$68.8M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -52.88 (distress)
- Working capital / assets 0.293
- Retained earnings / assets -13.783
- EBIT / assets -1.57
- Equity / liabilities 0.65
Source: SEC EDGAR filings · CIK 0001544227 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.